Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema
Tesofensine and GLP-1 medications like semaglutide and tirzepatide have distinct side effect profiles
Remarkably, BPC 157 demonstrates an exceptional wound healing concept, promoting healing not only in gastrointestinal ulcers but also in deep skin burns, injured muscles, tendons, ligaments, bones, and nerves, as well as in tissues like the cornea [ 8 ]
Preclinical studies suggest it supports tissue remodeling and epithelial repair, including recovery from abrasions, lacerations, and other skin injuries